{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:17:05Z","timestamp":1770884225572,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04543-8","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T08:13:34Z","timestamp":1755677614000},"page":"2275-2289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional combination of resveratrol and midostaurin induces cytotoxicity to overcome acquired midostaurin resistance in FLT3-ITD expressing acute myeloid leukemia cells"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-6415","authenticated-orcid":false,"given":"Melisa","family":"Tecik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3747-8580","authenticated-orcid":false,"given":"Aysun","family":"Adan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"4543_CR1","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1038\/s41375-022-01687-x","volume":"36","author":"C Allert","year":"2022","unstructured":"Allert C, Waclawiczek A, Zimmermann SMN, G\u00f6llner S, Heid D, Janssen M, Renders S, Rohde C, Bauer M, Bruckmann M, Zinz R, Pauli C, Besenbeck B, Wickenhauser C, Trumpp A, Krijgsveld J, M\u00fcller-Tidow C, Blank MF (2022) Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML. Leukemia 36:2418\u20132429. https:\/\/doi.org\/10.1038\/s41375-022-01687-x","journal-title":"Leukemia"},{"key":"4543_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A (2020) FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia 34:682\u2013696. https:\/\/doi.org\/10.1038\/s41375-019-0694-3","journal-title":"Leukemia"},{"key":"4543_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108461","volume":"689","author":"P Bian","year":"2020","unstructured":"Bian P, Hu W, Liu C, Li L (2020) Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K\/AKT\/mTOR pathway involved. Arch Biochem Biophys 689:108461. https:\/\/doi.org\/10.1016\/j.abb.2020.108461","journal-title":"Arch Biochem Biophys"},{"key":"4543_CR4","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.2174\/1381612811319300007","volume":"19","author":"A Borriello","year":"2013","unstructured":"Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Pirozzi AV, Oliva A, Della Ragione F (2013) Resveratrol and cancer treatment: is hormesis a yet unsolved matter? Curr Pharm des 19:5384\u20135393. https:\/\/doi.org\/10.2174\/1381612811319300007","journal-title":"Curr Pharm des"},{"key":"4543_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126322","volume":"22","author":"M Bostan","year":"2021","unstructured":"Bostan M, Mihaila M, Petrica-Matei GG, Radu N, Hainarosie R, Stefanescu CD, Roman V, Diaconu CC (2021) Resveratrol modulation of apoptosis and cell cycle response to cisplatin in head and neck cancer cell lines. Int J Mol Sci 22:6322. https:\/\/doi.org\/10.3390\/ijms22126322","journal-title":"Int J Mol Sci"},{"key":"4543_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054988","author":"A Brockmueller","year":"2023","unstructured":"Brockmueller A, Girisa S, Kunnumakkara AB, Shakibaei M (2023) Resveratrol modulates chemosensitisation to 5-FU via \u03b21-integrin\/HIF-1\u03b1 axis in CRC tumor microenvironment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24054988","journal-title":"Int J Mol Sci"},{"key":"4543_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00432-010-0884-x","volume":"137","author":"Z Cakir","year":"2011","unstructured":"Cakir Z, Saydam G, Sahin F, Baran Y (2011) The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol 137:279\u2013286. https:\/\/doi.org\/10.1007\/s00432-010-0884-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"4543_CR8","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.7150\/jca.34506","volume":"10","author":"J Chen","year":"2019","unstructured":"Chen J, Tian B, Zhou C, Sun J, Lin L, Jin S, Liu Q, Fu S, Liu L, Liu H, Zhang Z, Li C, Wei H (2019) A novel resveratrol-arsenic trioxide combination treatment synergistically induces apoptosis of adriamycin-selected drug-resistant leukemia K562 cells. J Cancer 10:5483\u20135493. https:\/\/doi.org\/10.7150\/jca.34506","journal-title":"J Cancer"},{"issue":"3","key":"4543_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"key":"4543_CR10","doi-asserted-by":"publisher","first-page":"32943","DOI":"10.18632\/oncotarget.25993","volume":"9","author":"SS Chung","year":"2018","unstructured":"Chung SS, Dutta P, Austin D, Wang P, Awad A, Vadgama JV (2018) Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget 9:32943\u201332957. https:\/\/doi.org\/10.18632\/oncotarget.25993","journal-title":"Oncotarget"},{"key":"4543_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8080245","author":"M Eguchi","year":"2020","unstructured":"Eguchi M, Minami Y, Kuzume A, Chi S (2020) Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8080245","journal-title":"Biomedicines"},{"key":"4543_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phymed.2018.06.046","volume":"55","author":"MZ El-Readi","year":"2019","unstructured":"El-Readi MZ, Eid S, Abdelghany AA, Al-Amoudi HS, Efferth T, Wink M (2019) Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. Phytomedicine 55:269\u2013281. https:\/\/doi.org\/10.1016\/j.phymed.2018.06.046","journal-title":"Phytomedicine"},{"key":"4543_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01627-2","volume":"39","author":"N Ers\u00f6z","year":"2022","unstructured":"Ers\u00f6z N, Adan A (2022) Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes. Med Oncol 39:35. https:\/\/doi.org\/10.1007\/s12032-021-01627-2","journal-title":"Med Oncol"},{"key":"4543_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215453","volume":"13","author":"F Frezzato","year":"2021","unstructured":"Frezzato F, Visentin A, Severin F, Pizzo S, Ruggeri E, Mouawad N, Martinello L, Pagnin E, Trimarco V, Tonini A, Carraro S, Pravato S, Imbergamo S, Manni S, Piazza F, Brunati AM, Facco M, Trentin L (2021) Targeting of HSP70\/HSF1 axis abrogates in vitro ibrutinib-resistance in chronic lymphocytic leukemia. Cancers 13:5453. https:\/\/doi.org\/10.3390\/cancers13215453","journal-title":"Cancers"},{"key":"4543_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s42003-021-02215-w","volume":"4","author":"A Garitano-Trojaola","year":"2021","unstructured":"Garitano-Trojaola A, Sancho A, G\u00f6tz R, Eiring P, Walz S, Jetani H, Gil-Pulido J, Da Via MC, Teufel E, Rhodes N, Haertle L, Arellano-Viera E, Tibes R, Rosenwald A, Rasche L, Hudecek M, Sauer M, Groll J, Einsele H, Kraus S, Kort\u00fcm MK (2021) Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Commun Biol 4:799. https:\/\/doi.org\/10.1038\/s42003-021-02215-w","journal-title":"Commun Biol"},{"key":"4543_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","volume":"31","author":"G Ghiaur","year":"2017","unstructured":"Ghiaur G, Levis M (2017) Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment. Hematol Oncol Clin North Am 31:681\u2013692. https:\/\/doi.org\/10.1016\/j.hoc.2017.04.005","journal-title":"Hematol Oncol Clin North Am"},{"key":"4543_CR17","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S (2012) An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev 6:e8. https:\/\/doi.org\/10.4081\/oncol.2012.e8","journal-title":"Oncol Rev"},{"key":"4543_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040925","author":"Y Han","year":"2019","unstructured":"Han Y, Jo H, Cho JH, Dhanasekaran DN, Song YS (2019) Resveratrol as a tumor-suppressive nutraceutical modulating tumor microenvironment and malignant behaviors of cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20040925","journal-title":"Int J Mol Sci"},{"key":"4543_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/16078454.2019.1666219","volume":"24","author":"X Hu","year":"2019","unstructured":"Hu X, Chen F (2019) Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia. Hematology 24:651\u2013660. https:\/\/doi.org\/10.1080\/16078454.2019.1666219","journal-title":"Hematology"},{"key":"4543_CR20","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1039\/C8RA08364A","volume":"9","author":"L Huang","year":"2019","unstructured":"Huang L, Zhang S, Zhou J, Li X (2019) Effect of resveratrol on drug resistance in colon cancer chemotherapy. RSC Adv 9:2572\u20132580. https:\/\/doi.org\/10.1039\/C8RA08364A","journal-title":"RSC Adv"},{"key":"4543_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbi.2019.04.001","volume":"306","author":"XT Huang","year":"2019","unstructured":"Huang XT, Li X, Xie ML, Huang Z, Huang YX, Wu GX, Peng ZR, Sun YN, Ming QL, Liu YX, Chen JP, Xu SN (2019) Resveratrol: review on its discovery, anti-leukemia effects and pharmacokinetics. Chem Biol Interact 306:29\u201338. https:\/\/doi.org\/10.1016\/j.cbi.2019.04.001","journal-title":"Chem Biol Interact"},{"key":"4543_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030718","volume":"9","author":"J Jodynis-Liebert","year":"2020","unstructured":"Jodynis-Liebert J, Kujawska M (2020) Biphasic dose-response induced by phytochemicals: experimental evidence. J Clin Med 9:718. https:\/\/doi.org\/10.3390\/jcm9030718","journal-title":"J Clin Med"},{"key":"4543_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/01635581.2011.538485","volume":"63","author":"M Kartal","year":"2011","unstructured":"Kartal M, Saydam G, Sahin F, Baran Y (2011) Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer 63:637\u2013644. https:\/\/doi.org\/10.1080\/01635581.2011.538485","journal-title":"Nutr Cancer"},{"key":"4543_CR24","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/blood-2010-06-289207","volume":"118","author":"S Kharazi","year":"2011","unstructured":"Kharazi S, Mead AJ, Mansour A, Hultquist A, B\u00f6iers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, R\u00f6nnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE (2011) Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood 118:3613\u20133621. https:\/\/doi.org\/10.1182\/blood-2010-06-289207","journal-title":"Blood"},{"key":"4543_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0233-7","volume":"17","author":"C Kim","year":"2016","unstructured":"Kim C, Baek SH, Um JY, Shim BS, Ahn KS (2016) Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTP\u03b5 and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. BMC Nephrol 17:19. https:\/\/doi.org\/10.1186\/s12882-016-0233-7","journal-title":"BMC Nephrol"},{"key":"4543_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci 111:312\u2013322. https:\/\/doi.org\/10.1111\/cas.14274","journal-title":"Cancer Sci"},{"key":"4543_CR27","doi-asserted-by":"publisher","unstructured":"Kursvietiene L, Kopustinskiene DM, Staneviciene I, Mongirdiene A, Kubov\u00e1 K, Masteikova R, Bernatoniene J (2023) Anti-Cancer Properties of Resveratrol: a focus on its impact on mitochondrial functions. Antioxidants (Basel) 12. https:\/\/doi.org\/10.3390\/antiox12122056","DOI":"10.3390\/antiox12122056"},{"key":"4543_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bbrc.2010.03.147","volume":"395","author":"SH Kweon","year":"2010","unstructured":"Kweon SH, Song JH, Kim TS (2010) Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395:104\u2013110. https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.147","journal-title":"Biochem Biophys Res Commun"},{"key":"4543_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041537","author":"SSY Lam","year":"2020","unstructured":"Lam SSY, Leung AYH (2020) Overcoming resistance to FLT3 inhibitors in the treatment of FLT3-mutated AML. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21041537","journal-title":"Int J Mol Sci"},{"key":"4543_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11899-017-0381-2","volume":"12","author":"MB Leick","year":"2017","unstructured":"Leick MB, Levis MJ (2017) The future of targeting FLT3 activation in AML. Curr Hematol Malig Rep 12:153\u2013167. https:\/\/doi.org\/10.1007\/s11899-017-0381-2","journal-title":"Curr Hematol Malig Rep"},{"key":"4543_CR31","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3892\/or.2018.6336","volume":"39","author":"I Leon-Galicia","year":"2018","unstructured":"Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME, Garcia-Villa E, Bermudez-Cruz R, Garcia-Mena J, Herrera LA, Garc\u00eda-Carranc\u00e1 A, Gariglio P (2018) Resveratrol decreases Rad51 expression and sensitizes cisplatin-resistant MCF-7 breast cancer cells. Oncol Rep 39:3025\u20133033. https:\/\/doi.org\/10.3892\/or.2018.6336","journal-title":"Oncol Rep"},{"key":"4543_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/cad.0000000000000635","volume":"29","author":"Q Li","year":"2018","unstructured":"Li Q, Zhang L, Ma L, Bai X, Li X, Zhao M, Sui T (2018) Resveratrol inhibits STAT5 activation through the induction of SHP-1 and SHP-2 tyrosine phosphatases in chronic myelogenous leukemia cells. Anticancer Drugs 29:646\u2013651. https:\/\/doi.org\/10.1097\/cad.0000000000000635","journal-title":"Anticancer Drugs"},{"key":"4543_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/01635581.2019.1578387","volume":"71","author":"Y Li","year":"2019","unstructured":"Li Y, Guo Y, Feng Z, Bergan R, Li B, Qin Y, Zhao L, Zhang Z, Shi M (2019) Involvement of the PI3K\/Akt\/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60\/ADR cells. Nutr Cancer 71:1007\u20131018. https:\/\/doi.org\/10.1080\/01635581.2019.1578387","journal-title":"Nutr Cancer"},{"key":"4543_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/j.1476-5381.2012.01862.x","volume":"166","author":"KG Lim","year":"2012","unstructured":"Lim KG, Gray AI, Pyne S, Pyne NJ (2012) Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br J Pharmacol 166:1605\u20131616. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01862.x","journal-title":"Br J Pharmacol"},{"key":"4543_CR35","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1038\/onc.2016.41","volume":"35","author":"O Lindblad","year":"2016","unstructured":"Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg \u00c5, Levander F, Stegmaier K, Pietras K, R\u00f6nnstrand L, Kazi JU (2016) Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML. Oncogene 35:5119\u20135131. https:\/\/doi.org\/10.1038\/onc.2016.41","journal-title":"Oncogene"},{"key":"4543_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00734","author":"X Liu","year":"2019","unstructured":"Liu X, Li H, Wu M-L, Wu J, Sun Y, Zhang K-L, Liu J (2019) Resveratrol reverses retinoic acid resistance of anaplastic thyroid cancer cells via demethylating CRABP2 gene. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2019.00734","journal-title":"Front Endocrinol"},{"key":"4543_CR37","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.3892\/or.2016.4728","volume":"35","author":"R Medina-Aguilar","year":"2016","unstructured":"Medina-Aguilar R, Marchat LA, Arechaga Ocampo E, Gariglio P, Garc\u00eda Mena J, Villegas Sep\u00falveda N, Mart\u00ednez Castillo M, L\u00f3pez-Camarillo C (2016) Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells. Oncol Rep 35:3696\u20133704. https:\/\/doi.org\/10.3892\/or.2016.4728","journal-title":"Oncol Rep"},{"key":"4543_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810870","volume":"23","author":"A Momchilova","year":"2022","unstructured":"Momchilova A, Pankov R, Staneva G, Pankov S, Krastev P, Vassileva E, Hazarosova R, Krastev N, Robev B, Nikolova B, Pinkas A (2022) Resveratrol affects sphingolipid metabolism in A549 lung adenocarcinoma cells. Int J Mol Sci 23:10870. https:\/\/doi.org\/10.3390\/ijms231810870","journal-title":"Int J Mol Sci"},{"key":"4543_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.yexcr.2015.02.025","volume":"333","author":"J Newton","year":"2015","unstructured":"Newton J, Lima S, Maceyka M, Spiegel S (2015) Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp Cell Res 333:195\u2013200. https:\/\/doi.org\/10.1016\/j.yexcr.2015.02.025","journal-title":"Exp Cell Res"},{"key":"4543_CR40","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1080\/01635581.2021.2005806","volume":"74","author":"O O\u011fuz","year":"2022","unstructured":"O\u011fuz O, Adan A (2022) Involvement of sphingolipid metabolism enzymes in Resveratrol-mediated cytotoxicity in Philadelphia-positive acute lymphoblastic leukemia. Nutr Cancer 74:2508\u20132521. https:\/\/doi.org\/10.1080\/01635581.2021.2005806","journal-title":"Nutr Cancer"},{"key":"4543_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11596-015-1457-7","volume":"35","author":"DY Peng","year":"2015","unstructured":"Peng DY, Song H, Liu LB (2015) Resveratrol-downregulated phosphorylated liver kinase B1 is involved in senescence of acute myeloid leukemia stem cells. J Huazhong Univ Sci Technol Med Sci 35:485\u2013489. https:\/\/doi.org\/10.1007\/s11596-015-1457-7","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"4543_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400261","volume":"357","author":"AM Radwan","year":"2024","unstructured":"Radwan AM, Abosharaf HA, Sharaky M, Abdelmonem R, Effat H (2024) Functional combination of resveratrol and tamoxifen to overcome tamoxifen-resistance in breast cancer cells. Arch Pharm (Weinheim) 357:e2400261. https:\/\/doi.org\/10.1002\/ardp.202400261","journal-title":"Arch Pharm (Weinheim)"},{"key":"4543_CR43","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/nejmoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454\u2013464. https:\/\/doi.org\/10.1056\/nejmoa1614359","journal-title":"N Engl J Med"},{"key":"4543_CR44","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/jcb.26709","volume":"20","author":"M Talebi","year":"2019","unstructured":"Talebi M, Bahar Aghdam S, Azimi A, Mohammadi H, Karimi Yonjali S, Asariha M, Zadi Heydarabad M (2019) Regulatory effect of resveratrol and prednisolone on MDR1 protein expression in acute lymphoblastic leukemia cell line (CCRF-CEM). Asian Pac J Cancer Prev 20:1171\u20131176. https:\/\/doi.org\/10.1002\/jcb.26709","journal-title":"Asian Pac J Cancer Prev"},{"key":"4543_CR45","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/ott.s384293","volume":"15","author":"M Tecik","year":"2022","unstructured":"Tecik M, Adan A (2022) Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches. Onco Targets Ther 15:1449\u20131478. https:\/\/doi.org\/10.2147\/ott.s384293","journal-title":"Onco Targets Ther"},{"key":"4543_CR46","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11864-024-01202-7","volume":"25","author":"M Tecik","year":"2024","unstructured":"Tecik M, Adan A (2024) Emerging DNA methylome targets in FLT3-ITD-positive acute myeloid leukemia: combination therapy with clinically approved FLT3 inhibitors. Curr Treat Options Oncol 25:719\u2013751. https:\/\/doi.org\/10.1007\/s11864-024-01202-7","journal-title":"Curr Treat Options Oncol"},{"key":"4543_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009x.2025.2478340","volume":"1\u201317","author":"M Tecik","year":"2025","unstructured":"Tecik M, Adan A (2025) Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3\/STAT5A signaling to induce apoptosis. J Chemother 1\u201317:1. https:\/\/doi.org\/10.1080\/1120009x.2025.2478340","journal-title":"J Chemother"},{"key":"4543_CR48","first-page":"2755","volume":"8","author":"H Tian","year":"2015","unstructured":"Tian H, Yu Z (2015) Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway. Int J Clin Exp Pathol 8:2755\u20132762","journal-title":"Int J Clin Exp Pathol"},{"key":"4543_CR49","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/1878-0261.12640","volume":"14","author":"S Waldeck","year":"2020","unstructured":"Waldeck S, Rassner M, Keye P, Follo M, Herchenbach D, Endres C, Charlet A, Andrieux G, Salzer U, Boerries M, Duyster J, von Bubnoff N (2020) CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML. Mol Oncol 14:779\u2013794. https:\/\/doi.org\/10.1002\/1878-0261.12640","journal-title":"Mol Oncol"},{"key":"4543_CR50","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3892\/mmr.2017.6111","volume":"15","author":"S Wang","year":"2017","unstructured":"Wang S, Meng Q, Xie Q, Zhang M (2017) Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep 15:1179\u20131187. https:\/\/doi.org\/10.3892\/mmr.2017.6111","journal-title":"Mol Med Rep"},{"key":"4543_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0487-8","volume":"36","author":"J Xu","year":"2017","unstructured":"Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li J, Zhang Q (2017) Resveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN\/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res 36:19. https:\/\/doi.org\/10.1186\/s13046-016-0487-8","journal-title":"J Exp Clin Cancer Res"},{"key":"4543_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176682","volume":"977","author":"KH Yu","year":"2024","unstructured":"Yu KH, Wu IT, Yu CP, Wang WC, Chi CH, Tsai KC, Chou CH, Hung CC, Hung HY (2024) Discovery of oral chemotherapeutic reversal agents for treating multidrug resistance cancer. Eur J Pharmacol 977:176682. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176682","journal-title":"Eur J Pharmacol"},{"key":"4543_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110409","volume":"376","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang Z, Mousavi M, Moliani A, Bahman Y, Bagheri H (2023) Resveratrol inhibits glioblastoma cells and chemoresistance progression through blockade P-glycoprotein and targeting AKT\/PTEN signaling pathway. Chem Biol Interact 376:110409. https:\/\/doi.org\/10.1016\/j.cbi.2023.110409","journal-title":"Chem Biol Interact"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04543-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:54:54Z","timestamp":1770882894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04543-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04543-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}